Our novel small molecules reduce neurodegeneration, inflammation, and neurovascular injury when delivered following a stroke. M3T compounds suppress stroke-induced peripheral immune activation, reducing secondary tissue damage following a cardiovascular event.
M3T compounds in combination with clot dissolving Activase ® will increase the its therapeutic potential and the margin of safety of Activase during treatment. Shutting down activated immune cells would allow clot-busting medicines to be used past their window of therapeutic usefulness.
M3Ts discovery platform is the most advanced in the field of neurodegeneration, focusing on cellular and subcellular events and their modification during cerebrovascular injury and immune system activation. M3T compounds turn Damaging Immune Cells into Non-damaging Immune Cells, in newly uncovered mechanisms.
The Department of Defense has funded M3T to define and bring to military medicine new compounds for limiting CNS damage caused by critical blood loss, especially on the battlefield. Our novel chemistry, combined with our focused discovery platform, has lead to active compounds currently in IND enabling studies and expanded models of ischemic neurodegeneration.
Our goal is to advance our compounds into broad clinical use in Emergency Medicine with strategic partnerships aims in new treatments against neurodegeneration.
Copyright © 2022 M3 Therapeutics - All Rights Reserved.